Default company panoramic image

InCarda Therapeutics, Inc.

Pioneering development of transformative therapies that patients can self-administer to treat acute cardiovascular conditions in Afib and MI

  • Stage Product In Development
  • Industry Biotechnology
  • Location Palo Alto, CA, USA
  • Currency USD
  • Founded October 2009
  • Employees 3
  • Website

Company Summary

InCarda develops novel inhaled cardio therapies for acute cardiac conditions. Inhalation permits early treatment by delivering a bolus drug directly to the regions in the heart where stimuli for acute cardiac conditions arise. InCarda's lead product is intended to rapidly & safely convert Afib to normal rhythm in an outpatient setting. The Heart Attack Inhaler is to intended save lives of MI patients. Both indications have large worldwide markets


  • Default avatar
    John Patton, PhD
    Executive Chairman, Co-Founder

    John co-founded InCarda in 2009. He is an entrepreneur in drug delivery, particularly pulmonary and protein delivery. John was co-founder of Nektar where he was CSO from 1990-2008. He lead the development and FDA approval of the first inhaled insulin product. He also led drug delivery at Genentech (l985-1990). He is a Ph.D. in biology from UCSD, and held post-doc positions in biomedicine at Harvard Medical School and the Univ of Lund, Sweden.

  • Default avatar
    Narsi Rangachari, M. Pharm
    President, COO and Co-Founder

    He was first to identify inhaled cardiology drugs for acute cardiac conditions. Before this he was Managing Director of Nektar's Indian sub. He led globalizing Nektar’s R&D; implementing a proprietary prod. dev plan & leading proprietary drug dev projects. He was the global project management lead in Genpharm, Canada (Mylan). Before this he worked for > 10 yrs in India with many Indian companies. He is a M. Pharm from Nagpur University, India.

  • Default avatar
    Greg Marcus, MD
    Chief Medical Officer and Co-founder

    An Asst. Prof. of Medicine in the Electrophysiology and Dir of Clinical Res for the Div of Cardiology at UCSF. After completing his internship, residency, & Chief Residency in internal medicine at Stanford, he joined UCSF to complete his general cardiology and electrophysiology training. He regularly treats patients with cardiac arrhythmias in UCSF. He is a recognized expert in the evaluation and treatment of arrhythmias especially Afib.

  • Default avatar
    Carlos Schuler, PhD
    Chief Scientific Officer and Co-Founder

    He is responsible for Science & Tech integration. Carlos was VP of Ops at Talima Therapeutics, heading mfg, CMC & supply chain. Before this he was VP of CMC & Dev at Anesiva. Carlos was at Nektar for > 10 yrs in a variety of senior business/technical management roles in Prod Dev, basic research, and technology/process dev. Before this he was in the aerospace industry advancing programs funded by NASA. He is a Ph.D. from UC Berkeley in Mech. Eng.


  • Default avatar
    Hayden Bergman Prof. Corp; AND PABST Patent LLC
    Default avatar
    M.A. Pizarek

Previous Investors

  • Default avatar
    Default avatar
    Individual Angel investors